Aprea Therapeutics APRE 深 沪
等待开盘 06-30 09:30:00 美东时间
0.819
+0.029
+3.67%
华盛通- 最 高0.819
- 今 开0.7865
- 成交量 6.18万股
- 最 低 0.734
- 昨 收 0.79
- 总市值 1014.15万
- 52周最高 2.22
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 0.548
- 委 比 -49.81%
- 总股本 1238.28万
- 历史最高 1062.20
- 量 比 0.51
- 振 幅 10.76%
- 历史最低 0.548
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
06-01 20:08
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Aprea Therapeutics presented early results from the ACESOT-1051 Phase 1 study of APR-1051, a WEE1 inhibitor, at the 2026 ASCO meeting. Key highlights include partial responses and stable disease in multiple tumor types, manageable tolerability, and ongoing patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer. Dose escalation is expected to complete in Q2 2027. APR-1051 demonstrates promising safety and efficacy pr...
06-01 12:00
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.
05-14 21:17
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall Overview US precision oncology firm's Q1 net loss narrowed yr/yr as R&D expenses declined Cash and cash equivalents rose to $46.5 mln after $30 mln private placement Company observed two partial responses in ongoing Phase 1 APR-1051 trial O
05-13 18:37
Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 66.67 percent increase over losses of $(0.66) per share from
05-13 18:36
Aprea Therapeutics Q1 FY26 net loss narrows to $3.3 million
Aprea Therapeutics Q1 FY26 net loss narrows to $3.3 million Aprea Therapeutics posted a Q1 net loss of USD 3.29 million, narrowing from USD 3.93 million a year earlier, while loss per share improved to USD 0.22 from USD 0.66. Operating loss narrowed to USD 3.43 million from USD 4.09 million, as oper
05-13 18:30
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5
Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.
05-07 18:49
